Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members

Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members

Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions...

Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology

Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology

Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- Lunit...

New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images

New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images

Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered...

Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW

Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW

Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a...

Lunit and Volpara Unveiled Unified Ecosystem at RSNA 2024 to Transform Global Cancer Care

Lunit and Volpara Unveiled Unified Ecosystem at RSNA 2024 to Transform Global Cancer Care

Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- At this year's...

Real-World Validation: Lunit AI Proven Successful in 1-Year Breast Cancer Screening Deployment

Real-World Validation: Lunit AI Proven Successful in 1-Year Breast Cancer Screening Deployment

Follow-up to ScreenTrustCAD presented at RSNA 2024 highlights 1-year post-AI adoption success in improving cancer detection, radiologist workload, and screening efficiency SEOUL, South Korea, Dec. 2, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a...

Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging

Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging

AI-powered chest X-ray and mammography analysis solutions to be deployed across one of Mexico's largest healthcare networks SEOUL, South Korea, Nov. 27, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for...

Lunit to Showcase Research Contributions at RSNA 2024 with Record-Breaking 20 Abstracts

Lunit to Showcase Research Contributions at RSNA 2024 with Record-Breaking 20 Abstracts

Twenty studies validate AI performance across diverse populations and clinical settings, including award-winning research in emergency radiology SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of...

menu
menu